In summary, the study demonstrates the selective killing effect of EpCAM-specific CAR-NK-92 cells on colorectal cancer cells in vitro and highlights the potent combination therapy of CAR-NK-92 cells and regorafenib in suppressing tumor growth in a humanized CRC mouse model. This evidence concerns the gene EPCAM and neoplasm.